Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 5/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | SI | P14410 | 5/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911460 | 0.88 | MGAM (0.41) | SLC9A1HCAR3MGAMAMY1AGAA | |
| SCHEMBL28675633 | 0.86 | SLC9A1 (0.60) | SLC9A1HCAR3MGAMAMY1AGAA | |
| SCHEMBL28669951 | 0.86 | SLC9A1 (0.60) | SLC9A1HCAR3MGAMAMY1AGAA | |
| SCHEMBL28650701 | 0.86 | SLC9A1 (0.60) | SLC9A1HCAR3MGAMAMY1AGAA | |
| SCHEMBL19911498 | 0.84 | SLC9A1 (0.50) | SLC9A1HCAR3GAARAB9A | |
| SCHEMBL19911486 | 0.84 | SLC9A1 (0.50) | SLC9A1HCAR3RAB9A | |
| SCHEMBL19911445 | 0.82 | SLC9A1 (0.58) | SLC9A1HCAR3MGAMAMY1AGAA | |
| SCHEMBL19911623 | 0.81 | SLC9A1 (0.49) | SLC9A1HCAR3GRM2 | |
| SCHEMBL19911591 | 0.81 | SLC9A1 (0.49) | SLC9A1HCAR3NPC1 | |
| SCHEMBL19911605 | 0.81 | SLC9A1 (0.49) | SLC9A1HCAR3NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885MGAM 3479/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885MGAM 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.